CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2017-01-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.116.307122PMID 28126828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dysfunctional HDL and atherosclerotic cardiovascular disease

  2016cited by this paper
• Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation

  2016cited by this paper
• Chasing-and Catching-the Wild Goose: Hypothesis-Free Post-Hoc Stratification Studies as a New Paradigm for Drug Development.

  2015cited by this paper
• Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.

  2015cited by this paper
• Higher TNFα responses in young males compared to females are associated with attenuation of monocyte adenylyl cyclase expression.

  2015cited by this paper
• Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib

  2015cited by this paper
• Effects of extended-release niacin with laropiprant in high-risk patients.

  2014cited by this paper
• Functional annotation of non-coding sequence variants

  2014cited by this paper
• TAVI in a low left main coronary artery ostium and wide aortic sinus of Valsava.

  2014cited by this paper
• The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.

  2014cited by this paper
• Systematic identification of trans eQTLs as putative drivers of known disease associations

  2013cited by this paper
• An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.

  2012cited by this paper
• Effects of dalcetrapib in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy

  2011cited by this paper
• Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

  2011cited by this paper
• mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion.

  2010cited by this paper
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• miR‐142‐3p restricts cAMP production in CD4+CD25− T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA

  2009cited by this paper
• Cholesterol-dependent Separation of the β2-Adrenergic Receptor from Its Partners Determines Signaling Efficacy

  2008cited by this paper
• Identification of innate immunity genes and pathways using a comparative genomics approach

  2008cited by this paper
• Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL

  2007cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits

  2005cited by this paper
• Novel Regulatory Properties of Human Type 9 Adenylate Cyclase

  2004cited by this paper
• Protein Kinase A Site-specific Phosphorylation Regulates ATP-binding Cassette A1 (ABCA1)-mediated Phospholipid Efflux*

  2002cited by this paper
• cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200235-JLR200

  2002cited by this paper

• The Role of Lipids in Atherosclerosis: Focus on Molecular Biology Mechanisms and Therapeutic Approaches.

  2025cites this paper
• The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies

  2024cites this paper
• Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial

  2022cites this paper
• dal-GenE was negative-not positive except for COVID-19.

  2022cites this paper
• High-density lipoproteins: from quantitative measures to functional assessment and therapy (review of literature).

  2022cites this paper
• Atherosclerosis: Cholesterol Management

  2021cites this paper
• Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects

  2021cites this paper
• Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.

  2020cites this paper
• Design and development of novel therapeutics for coronary heart disease treatment based on cholesteryl ester transfer protein inhibition – in silico approach

  2020cites this paper
• Cholesteryl ester transfer protein inhibitors in precision medicine.

  2020cites this paper
• Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

  2020cites this paper
• The chilling of adenylyl cyclase 9 and its translational potential.

  2020cites this paper
• HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk.

  2019cites this paper
• Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease.

  2019cites this paper
• Endoplasmic reticulum stress‐dependent autophagy inhibits glycated high‐density lipoprotein‐induced macrophage apoptosis by inhibiting CHOP pathway

  2019cites this paper
• Impact of ADCY9 Genotype on Response to Anacetrapib

  2019cites this paper
• Recent Highlights of ATVB: Lipoproteins

  2018cites this paper
• CETP inhibition and ADCY9 genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease?

  2018cites this paper
• An update on trials of novel lipid-lowering drugs

  2018cites this paper
• High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis

  2018cites this paper
• Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.

  2018cites this paper
• Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis

  2018cites this paper
• The year in cardiology 2017: prevention

  2018cites this paper
• Present therapeutic role of cholesteryl ester transfer protein inhibitors

  2018cites this paper
• Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena

  2018cites this paper
• ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein)

  2018cites this paper
• Precision medicine to change the landscape of cardiovascular drug development

  2017cites this paper
• The renaissance of lipoprotein(a): Brave new world for preventive cardiology?

  2017cites this paper